Aptevo Therapeutics's EBIT per Share for the
three
months ended in Dec. 2023 was $-14.44.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-141.49.
During the past 3 years, the average EBIT per Share Growth Rate was 33.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 37.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 25.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Aptevo Therapeutics's EBIT per Share or its related term are showing as below:
APVO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -7.2 Med: 29.7 Max: 47.7
Current: 33.7
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Aptevo Therapeutics was 47.70% per year. The lowest was -7.20% per year. And the median was 29.70% per year.
APVO's 3-Year EBIT Growth Rate is ranked better than 83.54% of 1306
companies
in the Biotechnology industry
Industry Median: 3.5
vs APVO: 33.70
Aptevo Therapeutics EBIT per Share Historical Data
The historical data trend for Aptevo Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-141.49
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptevo Therapeutics (NAS:APVO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Aptevo Therapeutics EBIT per Share Related Terms
Thank you for viewing the detailed overview of Aptevo Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Aptevo Therapeutics (Aptevo Therapeutics) Business Description
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APVO has been successfully added to your 